Eone Diagnomics Genome Center Co., Ltd.

245620KOSDAQResearch and development

Eone Diagnomics Genome Center Co., Ltd. (245620, KOSDAQ) reported KRW 8bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
202388-9-3317439Consolidated
202431-9586-44Consolidated
202582844-23Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023-10.6%-37.3%22.5%-84.4%
2024-307.8%-51.4%215.1%
2025358.1%-51.2%-125.4%

Revenue moved -91.1% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 167bn
Close priceKRW 741
Listed shares225,531,114
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)63
Women36 (57.1%)
Average tenure3.5 years
Annual pay, menKRW 56,668,205
Annual pay, womenKRW 33,884,909
Pay ratio, women to men59.8%

Other companies in Research and development

63 listed companies file under this classification. Showing 12.

See the whole Research and development list →